← Patent-cliff monitor small molecule YEZTUGO LENACAPAVIR SODIUM
Loss of exclusivity November 2040 latest FDA-listed patent expiry
Drug detail Brand name YEZTUGO Active ingredient LENACAPAVIR SODIUM Strength EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval June 2025 Marketing status RX
Listed patents Patent Expires Type 11807625 November 2040 use U-4190 12594267 July 2039 product 11267799 August 2038 substance 10071985 August 2037 substance, product 9951043 February 2034 substance, product
Regulatory exclusivity Code Expires NP June 2028 NCE December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.